Sustained virological response after ten days of triple anti-hepatitis C virus (HCV) therapy with telaprevir plus pegylated interferon and ribavirin in an HIV/HCV co-infected cirrhotic woman
The introduction of first-generation protease inhibitors for the treatment of chronic hepatitis C in subjects infected with hepatitis C virus (HCV) genotype 1 has significantly improved the sustained virological response (SVR) rate. As liver cirrhosis reduces the probability of achieving SVR, curren...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2014-12-01
|
| Series: | International Journal of Infectious Diseases |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S1201971214016270 |
| _version_ | 1818757615310602240 |
|---|---|
| author | Hamid Hasson Emanuela Messina Marco Merli Liviana Della Torre Giulia Morsica Sabrina Bagaglio Adriano Lazzarin Caterina Uberti-Foppa |
| author_facet | Hamid Hasson Emanuela Messina Marco Merli Liviana Della Torre Giulia Morsica Sabrina Bagaglio Adriano Lazzarin Caterina Uberti-Foppa |
| author_sort | Hamid Hasson |
| collection | DOAJ |
| description | The introduction of first-generation protease inhibitors for the treatment of chronic hepatitis C in subjects infected with hepatitis C virus (HCV) genotype 1 has significantly improved the sustained virological response (SVR) rate. As liver cirrhosis reduces the probability of achieving SVR, current guidelines discourage response-guided therapy in cirrhotic patients. We report the first case of a cirrhotic woman with chronic HCV and HIV co-infection achieving virological response after an ultra-short course of therapy. A 40-year-old HIV/HCV co-infected woman with compensated liver cirrhosis was treated with anti-HCV triple therapy containing telaprevir plus pegylated interferon and ribavirin. Baseline plasma HCV RNA was 3.6 log IU/ml and transaminases were within the normal range. She harboured IL28B rs12979860 C/C alleles. Ten days after starting therapy, the patient stopped treatment because of mild anorexia and nausea. Virological response was detected at treatment discontinuation and was maintained up to 24 weeks. This case describes an unexpected SVR after a 10-day course of antiviral therapy in a cirrhotic HIV/HCV co-infected woman presenting positive predictive factors for a response (low viral load, IL28B genotype). Nonetheless, there is no evidence to suggest a shorter duration of treatment in this subset of patients. |
| first_indexed | 2024-12-18T06:13:45Z |
| format | Article |
| id | doaj.art-5440245531d4480b9228f24f4a8855b1 |
| institution | Directory Open Access Journal |
| issn | 1201-9712 1878-3511 |
| language | English |
| last_indexed | 2024-12-18T06:13:45Z |
| publishDate | 2014-12-01 |
| publisher | Elsevier |
| record_format | Article |
| series | International Journal of Infectious Diseases |
| spelling | doaj.art-5440245531d4480b9228f24f4a8855b12022-12-21T21:18:19ZengElsevierInternational Journal of Infectious Diseases1201-97121878-35112014-12-0129C10010210.1016/j.ijid.2014.08.011Sustained virological response after ten days of triple anti-hepatitis C virus (HCV) therapy with telaprevir plus pegylated interferon and ribavirin in an HIV/HCV co-infected cirrhotic womanHamid Hasson0Emanuela Messina1Marco Merli2Liviana Della Torre3Giulia Morsica4Sabrina Bagaglio5Adriano Lazzarin6Caterina Uberti-Foppa7Department of Infectious Diseases, IRCCS Ospedale San Raffaele, Via Stamira d’Ancona 20, 20127 Milan, ItalyDepartment of Infectious Diseases, IRCCS Ospedale San Raffaele, Via Stamira d’Ancona 20, 20127 Milan, ItalyDepartment of Infectious Diseases, IRCCS Ospedale San Raffaele, Via Stamira d’Ancona 20, 20127 Milan, ItalyDepartment of Infectious Diseases, IRCCS Ospedale San Raffaele, Via Stamira d’Ancona 20, 20127 Milan, ItalyDepartment of Infectious Diseases, IRCCS Ospedale San Raffaele, Via Stamira d’Ancona 20, 20127 Milan, ItalyDepartment of Infectious Diseases, IRCCS Ospedale San Raffaele, Via Stamira d’Ancona 20, 20127 Milan, ItalyDepartment of Infectious Diseases, IRCCS Ospedale San Raffaele, Via Stamira d’Ancona 20, 20127 Milan, ItalyDepartment of Infectious Diseases, IRCCS Ospedale San Raffaele, Via Stamira d’Ancona 20, 20127 Milan, ItalyThe introduction of first-generation protease inhibitors for the treatment of chronic hepatitis C in subjects infected with hepatitis C virus (HCV) genotype 1 has significantly improved the sustained virological response (SVR) rate. As liver cirrhosis reduces the probability of achieving SVR, current guidelines discourage response-guided therapy in cirrhotic patients. We report the first case of a cirrhotic woman with chronic HCV and HIV co-infection achieving virological response after an ultra-short course of therapy. A 40-year-old HIV/HCV co-infected woman with compensated liver cirrhosis was treated with anti-HCV triple therapy containing telaprevir plus pegylated interferon and ribavirin. Baseline plasma HCV RNA was 3.6 log IU/ml and transaminases were within the normal range. She harboured IL28B rs12979860 C/C alleles. Ten days after starting therapy, the patient stopped treatment because of mild anorexia and nausea. Virological response was detected at treatment discontinuation and was maintained up to 24 weeks. This case describes an unexpected SVR after a 10-day course of antiviral therapy in a cirrhotic HIV/HCV co-infected woman presenting positive predictive factors for a response (low viral load, IL28B genotype). Nonetheless, there is no evidence to suggest a shorter duration of treatment in this subset of patients.http://www.sciencedirect.com/science/article/pii/S1201971214016270TelaprevirHIV/HCV co-infectionLiver cirrhosis |
| spellingShingle | Hamid Hasson Emanuela Messina Marco Merli Liviana Della Torre Giulia Morsica Sabrina Bagaglio Adriano Lazzarin Caterina Uberti-Foppa Sustained virological response after ten days of triple anti-hepatitis C virus (HCV) therapy with telaprevir plus pegylated interferon and ribavirin in an HIV/HCV co-infected cirrhotic woman International Journal of Infectious Diseases Telaprevir HIV/HCV co-infection Liver cirrhosis |
| title | Sustained virological response after ten days of triple anti-hepatitis C virus (HCV) therapy with telaprevir plus pegylated interferon and ribavirin in an HIV/HCV co-infected cirrhotic woman |
| title_full | Sustained virological response after ten days of triple anti-hepatitis C virus (HCV) therapy with telaprevir plus pegylated interferon and ribavirin in an HIV/HCV co-infected cirrhotic woman |
| title_fullStr | Sustained virological response after ten days of triple anti-hepatitis C virus (HCV) therapy with telaprevir plus pegylated interferon and ribavirin in an HIV/HCV co-infected cirrhotic woman |
| title_full_unstemmed | Sustained virological response after ten days of triple anti-hepatitis C virus (HCV) therapy with telaprevir plus pegylated interferon and ribavirin in an HIV/HCV co-infected cirrhotic woman |
| title_short | Sustained virological response after ten days of triple anti-hepatitis C virus (HCV) therapy with telaprevir plus pegylated interferon and ribavirin in an HIV/HCV co-infected cirrhotic woman |
| title_sort | sustained virological response after ten days of triple anti hepatitis c virus hcv therapy with telaprevir plus pegylated interferon and ribavirin in an hiv hcv co infected cirrhotic woman |
| topic | Telaprevir HIV/HCV co-infection Liver cirrhosis |
| url | http://www.sciencedirect.com/science/article/pii/S1201971214016270 |
| work_keys_str_mv | AT hamidhasson sustainedvirologicalresponseaftertendaysoftripleantihepatitiscvirushcvtherapywithtelaprevirpluspegylatedinterferonandribavirininanhivhcvcoinfectedcirrhoticwoman AT emanuelamessina sustainedvirologicalresponseaftertendaysoftripleantihepatitiscvirushcvtherapywithtelaprevirpluspegylatedinterferonandribavirininanhivhcvcoinfectedcirrhoticwoman AT marcomerli sustainedvirologicalresponseaftertendaysoftripleantihepatitiscvirushcvtherapywithtelaprevirpluspegylatedinterferonandribavirininanhivhcvcoinfectedcirrhoticwoman AT livianadellatorre sustainedvirologicalresponseaftertendaysoftripleantihepatitiscvirushcvtherapywithtelaprevirpluspegylatedinterferonandribavirininanhivhcvcoinfectedcirrhoticwoman AT giuliamorsica sustainedvirologicalresponseaftertendaysoftripleantihepatitiscvirushcvtherapywithtelaprevirpluspegylatedinterferonandribavirininanhivhcvcoinfectedcirrhoticwoman AT sabrinabagaglio sustainedvirologicalresponseaftertendaysoftripleantihepatitiscvirushcvtherapywithtelaprevirpluspegylatedinterferonandribavirininanhivhcvcoinfectedcirrhoticwoman AT adrianolazzarin sustainedvirologicalresponseaftertendaysoftripleantihepatitiscvirushcvtherapywithtelaprevirpluspegylatedinterferonandribavirininanhivhcvcoinfectedcirrhoticwoman AT caterinaubertifoppa sustainedvirologicalresponseaftertendaysoftripleantihepatitiscvirushcvtherapywithtelaprevirpluspegylatedinterferonandribavirininanhivhcvcoinfectedcirrhoticwoman |